Esther van Twuijver
Art Innovation (Netherlands)(NL)Seqirus (United States)(US)
Publications by Year
Research Areas
Influenza Virus Research Studies, Respiratory viral infections research, Allergic Rhinitis and Sensitization, Asthma and respiratory diseases, Immune Response and Inflammation
Most-Cited Works
- → A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT‐birch pollen extract for the treatment of allergic rhinitis: results of a phase II study(2015)46 cited
- → Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Grass Pollen Preparation(2012)27 cited
- → SCIT-treatment With a Chemically Modified, Aluminum Hydroxide Adsorbed Peanut Extract (HAL-MPE1) Was Generally Safe And Well Tolerated And Showed Immunological Changes In Peanut Allergic Patients(2017)27 cited
- → A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations(2014)11 cited
- → Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects(2021)10 cited
- → Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults(2023)10 cited
- → Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults(2021)7 cited
- → Blood, blood components, plasma, and plasma products(2009)4 cited
- → Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects(2022)3 cited
- → Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions(2024)3 cited